Vitespen Terminated Phase 2 Trials for Renal Cell Adenocarcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01147536Immune Response Following Treatment of Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence